1.
Journal of International Pharmaceutical Research
;
(6): 669-675, 2017.
Artigo
em Chinês
| WPRIM
| ID: wpr-668007
RESUMO
Recently,programmed cell death 1/programmed cell death 1 ligand(PD-1/PD-L1)blockade has elicited clinical re-sponses and long-term remissions in a subset of patients with a broad spectrum of cancers. Unfortunately,a substantial number of pa-tients failed to respond to PD1/PD-L1 blockade. In this paper,we summarize our current understanding of the key factors accounting for the difference on treatment,and evaluate the dependability of several potential predictive biomarkers guiding PD1/PD-L1 blockade in cancer therapy. We also discuss a variety of combined treatments based on PD1/PD-L1 blockade.